Cellectar Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | $-0.57 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | $-1.33 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-1.41 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.14 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 18, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | $-0.74 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
Press releases
Announcements Cellectar Biosciences filed with the SEC
Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Cellectar Biosciences Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Cellectar Biosciences Announces European Medicines
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
FLORHAM PARK, N.J., June 18, 2025 -- Cellectar
Other events · EX-99.1 to Form 8-K
Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Cellectar Announces Plan to Explore Strategic Alternatives
Other events · EX-99.1 to Form 8-K
Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
to Highlight 2025 Strategic Initiatives at Upcoming
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cellectar Biosciences Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Compliance Regarding Filing of Form 10-Q
Other events · EX-99.1 CHARTER to Form 8-K
Cellectar to Restate Previously Issued Financial
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Financial Results for Q2 2024 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Cellectar Biosciences Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Cellectar Biosciences Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Results of operations · EX-99.1 to Form 8-K
Results for Second Quarter 2023 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
a Research and Development Program Summary
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Results for First Quarter 2023 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Results for Year Ended 2022 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Results for Third Quarter 2022 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Cellectar Biosciences Announces Concurrent Registered Direct and
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Cellectar Biosciences Announces Closing of Concurrent Registered
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple
Other events · EX-99.1 to Form 8-K
Results for Second Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Florham Park, N.J., July 21, 2022
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Results for First Quarter 2022 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Positive DMC Review of Pivotal Trial of
Regulation FD disclosure · EX-99.1 to Form 8-K
Results for Year Ended December 2021 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation March 2022 N A S D A Q : C L RB
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Poster Presentation at the
Regulation FD disclosure · EX-99.1 to Form 8-K
Data from its Ongoing Phase 2 CLOVER-1 Study of
Regulation FD disclosure · EX-99.2 to Form 8-K